The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Open accessAbstract
Objective The metabolic side effects of second-generation antipsychotics (SGA) are serious and have not been compared head to head in a meta-analysis. We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine. Method We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE and EMBASE (last search January 2009) for randomized, blinded studies comparing the above mentioned SGA in the treatment of schizophrenia or related disorders. At least three reviewers extracted the data independently. The primary outcome was weight change. We also assessed changes of cholesterol and glucose. The results were combined in a meta-analysis. Results We included 48 studies with 105 relevant arms. Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found. Clozapine produced more weight gain than risperidone, risperidone more than amisulpride, and sertindole more than risperidone. Olanzapine produced more cholesterol increase than aripiprazole, risperidone and ziprasidone. (No differences with amisulpride, clozapine and quetiapine were found). Quetiapine produced more cholesterol increase than risperidone and ziprasidone. Olanzapine produced more increase in glucose than amisulpride, aripiprazole, quetiapine, risperidone and ziprasidone; no difference was found with clozapine. Conclusions Some SGAs lead to substantially more metabolic side effects than other SGAs. When choosing an SGA for an individual patient these side effects with their potential cause of secondary diseases must be weighed against efficacy and characteristics of the individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 1×
“…for CVD such as obesity, smoking, diabetes, hypertension and dyslipidemia are more common in patients with schizophrenia than in the general population (Fleischhacker et al., 2008), and, in addition, antipsychotic medication can induce weight gain or worsen CVD risk factors (De Hert et al., 2009).”
BackgroundBassuk, S. S., & Manson, J. E. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00160.2005 · Cited by 744
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citationHjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30078-0 · Cited by 1,304
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“among antipsychotics, that has been confirmed in different studies and meta-analyses (11,23-33).”
ResultHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 327
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Foley, D. L., & Morley, K. I. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2 · Cited by 287
Callaghan, R. C., Veldhuizen, S., Jeysingh, T., Orlan, C., Graham, C., Kakouris, G., Remington, G., & Gatley, J. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.09.014 · Cited by 255
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
Schizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-340 · Cited by 188
“Oral SGA induced fewer extrapyramidal side effects than oral FGA but some SGA induced more weight gain or metabolic side effects than oral FGA [41,42].”
BackgroundStratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Vancampfort, D., Probst, M., Scheewe, T., De Herdt, A., Sweers, K., Knapen, J., van Winkel, R., & De Hert, M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.026 · Cited by 173
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Leung, J. Y. T., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.003 · Cited by 163
Association between antipsychotic medication use and diabetes
Holt, R. I. G. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1220-8 · Cited by 162
Tobacco Use Before, At, and After First-Episode Psychosis: A Systematic Meta-Analysis
Myles, N., Newall, H. D., Curtis, J., Nielssen, O., Shiers, D., & Large, M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07222 · Cited by 158
Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia
Vancampfort, D., Probst, M., Knapen, J., Carraro, A., & De Hert, M. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.03.046 · Cited by 149
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145
Weight gain and metabolic changes during treatment with antipsychotics and antidepressants
Himmerich, H., Minkwitz, J., & Kirkby, K. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150623092031 · Cited by 122
Sandhya, L., Devi Sreenivasan, N., Goenka, L., Dubashi, B., Kayal, S., Solaiappan, M., Govindarajalou, R., KT, H., & Ganesan, P. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01997 · Cited by 115
Scigliano, G., & Ronchetti, G. (2013) · CNS Drugs · doi:10.1007/s40263-013-0054-1 · Cited by 92
Antipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
“Most antipsychotics cause weight gain of some degree, and some of the “atypical” antipsychotics can cause extreme weight gain, glucose and lipid abnormalities, and diabetes [38,39].”
BackgroundCarolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., Hahn, M. K., Krivoy, A., Lally, J., Leucht, S., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae205 · Cited by 70
Self-citationReynolds, G. P., & McGowan, O. O. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722987 · Cited by 67
“Others have demonstrated antipsychotic-associated insulin resistance (Henderson et al., 2005) with the greatest effects on glucose elevation with olanzapine and clozapine (Newcomer, 2005; Rummel-Kluge et al., 2010).”
BackgroundMethodMetabolic Syndrome and Bipolar Disorder: What Should Psychiatrists Know?
de Almeida, K. M., Moreira, C. L. R. L., & Lafer, B. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00240.x · Cited by 64
Hughes, S., & Cohen, D. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.1716 · Cited by 57
“Since the release of quetiapine on the US market in 2002, weight gain and metabolic disorders have been recognized as significant problems for all atypical antipsychotics, though quetiapine is typically regarded as causing less weight gain than other medications in its class [44-46].”
BackgroundA multiple imputation strategy for sequential multiple assignment randomized trials
Shortreed, S. M., Laber, E., Scott Stroup, T., Pineau, J., & Murphy, S. A. (2014) · Statistics in Medicine · doi:10.1002/sim.6223 · Cited by 61
“Weight gain, captured by BMI, is an important side effect associated with many antipsychotics that impacts a patient’s overall health and their likelihood to adhere to treatment [36, 37].”
BackgroundForbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52
“In addition to weight gain, metabolic side effects such as elevated lipids, glucose, and prolactin are a serious concern with some second-generation antipsychotics (Rummel-Kluge et al., 2010; Leucht et al., 2013).”
BackgroundKato, T., Ishigooka, J., Miyajima, M., Watabe, K., Fujimori, T., Masuda, T., Higuchi, T., & Vieta, E. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13137 · Cited by 49
“Both olanzapine and quetiapine have higher affinity for histamine H1 and 5-HT2C receptors, which have been shown to be associated with glucose intolerance and increased insulin resistance, and both have a known characteristic to increase weight and elevate lipids.(52,53) Although detailed comparisons must be made caut…”
BackgroundMental health professionals’ views and experiences of antipsychotic reduction and discontinuation
Cooper, R. E., Hanratty, É., Morant, N., & Moncrieff, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218711 · Cited by 49
Rotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.118 · Cited by 48
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
de Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39
The prevention of diabetes and cardiovascular disease in people with schizophrenia
Holt, R. I. G. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12443 · Cited by 37
Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34
Benachenhou, S., Etcheverry, A., Galarneau, L., Dubé, J., & Çaku, A. (2019) · Autism Research · doi:10.1002/aur.2183 · Cited by 33
“Most treated participants were taking antipsychotics associated with higher cholesterol levels (risperidone, olanzapine, or quetiapine) [Rummel-Kluge et al., 2010] and only three participants were taking antipsychotics associated with lower cholesterol (aripiprazole, haloperidol, or trazodone)…”
BackgroundAntipsychotic-Induced Increase in Lipid Biosynthesis: Activation through Inhibition?
Skrede, S., Steen, V. M., & Fern⊘, J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.e034736 · Cited by 23
“Clozapine is clearly the most metabolically unfavourable drug in patients, while ziprasidone and haloperidol have minor effects on serum lipids and other metabolic parameters (1, 24, 25).”
BackgroundKluge, M., Himmerich, H., Wehmeier, P. M., Rummel-Kluge, C., Dalal, M., Hinze-Selch, D., Kraus, T., Dittmann, R. W., Pollmächer, T., & Schuld, A. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.12.017 · Cited by 22
Self-citationAndrade, C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12130 · Cited by 18
Othman, N. O., Abdel-Aal, H. H., Elsherief, W. A., Farag, D. E., Hunter, C. N., & Alsirafy, S. A. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.7033 · Cited by 11
Plasma oxysterols in drug-free patients with schizophrenia
Guidara, W., Messedi, M., Naifar, M., Maalej, M., Khrouf, W., Grayaa, S., Maalej, M., Bonnefont-Rousselot, D., Lamari, F., & Ayadi, F. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106123 · Cited by 11
Metadata
- Authors
- Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 123
- Issue
- 2-3
- Pages
- 225-233
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2061525750
- Cited by
- 675
- References
- 38
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.